

Systematic review of real-world evidence on overall survival in first-line advanced/metastatic cancer patients before and after the approval of anti-PD-(L)1 therapy

Katherine G Akers¹, Dweeti Nayak¹, Andrew M. Frederickson¹, Yves PV Mbous², Raquel Aguiar-Ibáñez^{3*}

¹Precision AQ, New York, NY, USA; ²Merck & Co., Inc., Rahway, NJ, USA; ³Merck Canada Inc., Kirkland, QC, Canada; *Presenting author: raquel.aguiar-ibanez@merck.com

References for included studies

Advanced/metastatic melanoma

1. Fennira F, Pages C, Schneider P, et al. Vemurafenib in the French temporary authorization for use metastatic melanoma cohort: A single-centre trial. *Melanoma Research*. 2014;24(1):75-82. doi:<https://dx.doi.org/10.1097/CMR.0000000000000034>
2. Ab Rahman AS, Strother RM, Paddison J. New Zealand national retrospective cohort study of survival outcomes of patients with metastatic melanoma receiving immune-checkpoint inhibitors. *Asia-Pacific Journal of Clinical Oncology*. February 2023;19(1):179-186. doi:<https://dx.doi.org/10.1111/ajco.13801>
3. Afrasanie VA, Alexa-Stratulat T, Gafton B, et al. Real Check RIO: A Real-World Analysis of Nivolumab in First Line Metastatic Melanoma Assessing Efficacy, Safety and Predictive Factors. *Cancers*. February 2023;15(4) (no pagination)1265. doi:<https://dx.doi.org/10.3390/cancers15041265>
4. Afzal MZ, Shirai K. Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumab in malignant melanoma: A retrospective analysis at a tertiary care center. *Melanoma Research*. 01 Aug 2018;28(4):341-347. doi:<https://dx.doi.org/10.1097/CMR.0000000000000459>
5. Amaral T, Seeber O, Mersi E, et al. Primary resistance to pd-1-based immunotherapy- a study in 319 patients with stage iv melanoma. *Cancers*. April 2020;12(4) (no pagination)1027. doi:<https://dx.doi.org/10.3390/cancers12041027>
6. Board R, Smittenaar R, Lawton S, et al. Metastatic melanoma patient outcomes since introduction of immune checkpoint inhibitors in England between 2014 and 2018. *International Journal of Cancer*. 15 Feb 2021;148(4):868-875. doi:<https://dx.doi.org/10.1002/ijc.33266>
7. Casarotto E, Chandwani S, Mortier L, et al. Real-world effectiveness of pembrolizumab in advanced melanoma: analysis of a French national clinicobiological database. *Immunotherapy*. 2021;02doi:<https://dx.doi.org/10.2217/imt-2021-0077>
8. Cowey CL, Boyd M, Aguilar KM, Beeks A, Krepler C, Scherrer E. An observational study of drug utilization and associated outcomes among adult patients diagnosed with BRAF-mutant advanced melanoma treated with first-line anti-PD-1 monotherapies or BRAF/MEK inhibitors in a community-based oncology setting. *Cancer Medicine*. 01 Nov 2020;9(21):7863-7878. doi:<https://dx.doi.org/10.1002/cam4.3312>

9. Cowey CL, Liu FX, Black-Shinn J, et al. Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices. *Journal of Immunotherapy*. 2018;41(2):86-95. doi:<https://dx.doi.org/10.1097/CJI.0000000000000204>
10. Cowey CL, Scherrer E, Boyd M, Aguilar KM, Beeks A, Krepler C. Pembrolizumab Utilization and Clinical Outcomes Among Patients With Advanced Melanoma in the US Community Oncology Setting: An Updated Analysis. *Journal of immunotherapy*. 1997;(pagination)doi:<https://dx.doi.org/10.1097/CJI.0000000000000363>
11. Czarnecka AM, Teterycz P, Mariuk-Jarema A, et al. Treatment Sequencing and Clinical Outcomes in BRAF-Positive and BRAF-Negative Unresectable and Metastatic Melanoma Patients Treated with New Systemic Therapies in Routine Practice. *Targeted oncology*. 2019;21doi:<https://dx.doi.org/10.1007/s11523-019-00688-8>
12. Hribnik N, Boc M, Ocvirk J, et al. Retrospective analysis of treatment-naïve Slovenian patients with metastatic melanoma treated with pembrolizumab-real-world experience. *Radiology and Oncology*. 19 Jan 2020;54(1):119-127. doi:<https://dx.doi.org/10.2478/raon-2020-0003>
13. Hurkmans DP, Jensen C, Koolen SLW, et al. Blood-based extracellular matrix biomarkers are correlated with clinical outcome after PD-1 inhibition in patients with metastatic melanoma. *Journal for ImmunoTherapy of Cancer*. 22 Oct 2020;8(2) (no pagination)e001193. doi:<https://dx.doi.org/10.1136/jitc-2020-001193>
14. Inozume T, Namikawa K, Kato H, et al. Analyzing the relationship between the efficacy of first-line immune checkpoint inhibitors and cumulative sun damage in Japanese patients with advanced BRAF wild-type nonacral cutaneous melanoma: A retrospective real-world, multicenter study. *Multicenter Study. J Dermatol Sci*. Apr 2023;110(1):19-26. doi:<https://dx.doi.org/10.1016/j.jdermsci.2023.03.008>
15. Iravani A, Wallace R, Lo SN, et al. FDG PET/CT Prognostic Markers in Patients with Advanced Melanoma Treated with Ipilimumab and Nivolumab. *Radiology*. May 2023;307(3) (no pagination)e221180. doi:<https://dx.doi.org/10.1148/RADIOL.221180>
16. Kartolo A, Yeung C, Kuksis M, Hopman W, Baetz T. Improved overall survival in dual compared to single immune checkpoint inhibitors in BRAF V600-negative advanced melanoma. *Melanoma Management*. March 2022;9(1) (no pagination)Mmt60. doi:<https://dx.doi.org/10.2217/mmt-2021-0005>
17. Kuzmanovszki D, Kiss N, Toth B, et al. Anti-PD-1 Monotherapy in Advanced Melanoma-Real-World Data from a 77-Month-Long Retrospective Observational Study. *Biomedicines*. Jul 19 2022;10(7):19. doi:<https://dx.doi.org/10.3390/biomedicines10071737>
18. Liu FX, Ou W, Diede SJ, Whitman ED. Real-world experience with pembrolizumab in patients with advanced melanoma: A large retrospective observational study. *Medicine*. 01 Jul 2019;98(30):e16542. doi:<https://dx.doi.org/10.1097/MD.00000000000016542>
19. Mason R, Dearden HC, Nguyen B, et al. Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma. *Pigment Cell and Melanoma Research*. 01 Mar 2020;33(2):358-365. doi:<https://dx.doi.org/10.1111/pcmr.12831>
20. Mohr P, Scherrer E, Assaf C, et al. Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany. *Cancers*. April-1 2022;14(7) (no pagination)1804. doi:<https://dx.doi.org/10.3390/cancers14071804>
21. Monestier S, Dalle S, Mortier L, et al. Effectiveness and Safety of Nivolumab in Patients with Advanced Melanoma: A Multicenter, Observational Study. *International journal of cancer*. 2021;111doi:<https://dx.doi.org/10.1002/ijc.33467>

22. O'Sullivan DE, Boyne DJ, Gogna P, Brenner DR, Cheung WY. Understanding Real-World Treatment Patterns and Clinical Outcomes among Metastatic Melanoma Patients in Alberta, Canada. *Current Oncology*. April 2023;30(4):4166-4176. doi:<https://dx.doi.org/10.3390/curroncol30040317>
23. Parakh S, Randhawa M, Nguyen B, et al. Real-world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanoma. *Asia-Pacific Journal of Clinical Oncology*. February 2019;15(1):26-30. doi:<https://dx.doi.org/10.1111/ajco.13100>
24. Pavlick AC, Zhao R, Lee CH, Ritchings C, Rao S. First-line immunotherapy versus targeted therapy in patients with BRAF-mutant advanced melanoma: A real-world analysis. *Future Oncology*. February 2021;17(6):689-699. doi:<https://dx.doi.org/10.2217/fo-2020-0643>
25. Peisen F, Hansch A, Hering A, et al. Combination of Whole-Body Baseline CT Radiomics and Clinical Parameters to Predict Response and Survival in a Stage-IV Melanoma Cohort Undergoing Immunotherapy. *Cancers*. June-2 2022;14(12) (no pagination)2992. doi:<https://dx.doi.org/10.3390/cancers14122992>
26. Rivas A, Delyon J, Martineau A, et al. 18FDG PET Assessment of Therapeutic Response in Patients with Advanced or Metastatic Melanoma Treated with First-Line Immune Checkpoint Inhibitors. *Cancers*. July-1 2022;14(13) (no pagination)3190. doi:<https://dx.doi.org/10.3390/cancers14133190>
27. Stein C, Burtsey S, Mancini J, et al. Acute kidney injury in patients treated with anti-programmed death receptor-1 for advanced melanoma: a real-life study in a single-centre cohort. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association European Renal Association*. 2020;17doi:<https://dx.doi.org/10.1093/ndt/gfaa137>
28. Suo A, Chan Y, Beaulieu C, et al. Anti-PD1-Induced Immune-Related Adverse Events and Survival Outcomes in Advanced Melanoma. *The oncologist*. 2020;12doi:<https://dx.doi.org/10.1634/theoncologist.2019-0674>
29. Tarhini A, Atzinger C, Gupte-Singh K, Johnson C, Macahilig C, Rao S. Treatment patterns and outcomes for patients with unresectable stage III and metastatic melanoma in the USA. *Journal of Comparative Effectiveness Research*. 01 May 2019;8(7):461-473. doi:<https://dx.doi.org/10.2217/ce-2019-0003>
30. van Breeschoten J, Wouters MWJM, Hilarius DL, et al. First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF^{>V600}-mutant advanced melanoma patients: a propensity-matched survival analysis. *British Journal of Cancer*. 30 Mar 2021;124(7):1222-1230. doi:<https://dx.doi.org/10.1038/s41416-020-01229-1>
31. Van Zeijl MCT, Haanen JBAG, Wouters MWJM, et al. Real-world Outcomes of First-line Anti-PD-1 Therapy for Advanced Melanoma: A Nationwide Population-based Study. *Journal of Immunotherapy*. 01 Oct 2020;43(8):256-264. doi:<https://dx.doi.org/10.1097/CJI.0000000000000334>
32. Van Zeijl MCT, Van Breeschoten J, De Wreede LC, et al. Real-world Outcomes of Ipilimumab Plus Nivolumab Combination Therapy in a Nation-wide Cohort of Advanced Melanoma Patients in the Netherlands. *Journal of Immunotherapy*. 01 Jun 2023;46(5):197-204. doi:<https://dx.doi.org/10.1097/CJI.0000000000000468>
33. Wei KZ, Baxter M, Casasola R. Hypophysitis induced by immune checkpoint inhibitors in a Scottish melanoma population. *Melanoma Management*. 2019;6(1) (no pagination)Mmt13. doi:<https://dx.doi.org/10.2217/mmt-2018-0009>
34. Wilson T, Taylor H, Winter H, Herbert C. Sequential immunotherapy in melanoma: is it a realistic alternative to dual immunotherapy? *Melanoma Research*. 08 01 2021;31(4):366-370. doi:<https://dx.doi.org/10.1097/CMR.0000000000000746>

35. Zaremba A, Mohr P, Gutzmer R, et al. Immune checkpoint inhibition in patients with NRAS mutated and NRAS wild type melanoma: a multicenter Dermatologic Cooperative Oncology Group study on 637 patients from the prospective skin cancer registry ADOREG. *European Journal of Cancer*. July 2023;188:140-151. doi:<https://dx.doi.org/10.1016/j.ejca.2023.04.008>

Advanced/metastatic non-small cell lung cancer

1. Abernethy AP, Arunachalam A, Burke T, et al. Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting. *Observational Study. PLoS ONE [Electronic Resource]*. 2017;12(6):e0178420. doi:<https://dx.doi.org/10.1371/journal.pone.0178420>
2. Banna GL, Anile G, Russo G, et al. Predictive and Prognostic Value of Early Disease Progression by PET Evaluation in Advanced Non-Small Cell Lung Cancer. *Oncology (Switzerland)*. 01 Jan 2017;92(1):39-47. doi:<https://dx.doi.org/10.1159/000448005>
3. Bonanno L, Paoli AD, Zulato E, et al. LKB1 Expression Correlates with Increased Survival in Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy and Bevacizumab. *Clinical Cancer Research*. 01 Jul 2017;23(13):3316-3324. doi:<https://dx.doi.org/10.1158/1078-0432.CCR-16-2410>
4. Camerini A, Chella A, Mazzoni F, et al. First-line treatment of NSCLC with bevacizumab: real world data from an Italian regional based survey. *J Chemother*. Feb 2017;29(1):38-41. doi:<https://dx.doi.org/10.1080/1120009X.2016.1219498>
5. Chen X, Zhu Q, Liu Y, et al. Icotinib is an active treatment of non-small-cell lung cancer: a retrospective study. *Research Support, Non-U.S. Gov't. PLoS ONE [Electronic Resource]*. 2014;9(5):e95897. doi:<https://dx.doi.org/10.1371/journal.pone.0095897>
6. Elsamany SA, Al-Fayea TM, Alzahrani AS, et al. Thyroid transcription factor-1 expression in advanced non- small cell lung cancer: impact on survival outcome. *Asian Pacific journal of cancer prevention : APJCP*. 2015;16(7):2987-2991.
7. Isobe H, Mori K, Minato K, et al. Real-world practice patterns for patients with advanced non-small cell lung cancer: multicenter retrospective cohort study in Japan. *Lung Cancer (Auckl)*. 2017;8:191-206. doi:<https://dx.doi.org/10.2147/LCTT.S140491>
8. Kohutek F, Stratena M, Rosik A, Tamasova M, Bystricky B. First-line treatment of nonsquamous NSCLC using gemcitabine: A retrospective study of real-life practice. *Lung Cancer Management*. November 2016;5(3):123-130. doi:<https://dx.doi.org/10.2217/lmt-2016-0011>
9. Mudad R, Patel MB, Margunato-Debay S, Garofalo D, Lal LS. Comparative effectiveness and safety of nab-paclitaxel plus carboplatin vs gemcitabine plus carboplatin in first-line treatment of advanced squamous cell non-small cell lung cancer in a US community oncology setting. *Lung Cancer: Targets and Therapy*. 19 Oct 2017;8:179-190. doi:<https://dx.doi.org/10.2147/LCTT.S139647>
10. Perez-Moreno MA, Cotrina-Luque J, Galvan-Banqueri M, Flores-Moreno S, Bautista-Paloma FJ, Calleja-Hernandez MA. Effectiveness and safety of pemetrexed for non-small cell lung cancer in the Andalusian Public Health System. *Multicenter Study; Observational Study. Farm*. Nov 01 2016;40(n06):477-485. Efectividad y seguridad del pemetrexed en el cancer de pulmon no microcitico en el Sistema Sanitario Publico de Andalucia.
11. de Castro J, Tagliaferri P, de Lima VCC, et al. Systemic therapy treatment patterns in patients with advanced non-small cell lung cancer (NSCLC): PivOTAL study. *Observational Study. Eur J Cancer Care (Engl)*. Nov 2017;26(6)doi:<https://dx.doi.org/10.1111/ecc.12734>
12. Shen L, Niu X, Jian H, Xu Y, Yu Y, Lu S. Assessment of interfering factors and clinical risk associated with discontinuation of pemetrexed maintenance therapy in advanced non-squamous non-small cell lung cancer. *Research Support, Non-U.S. Gov't. Lung Cancer*. 09 2017;111:43-50. doi:<https://dx.doi.org/10.1016/j.lungcan.2017.07.001>

13. Thippeswamy R, Patil S, Prashanth P, et al. Outcomes in lung cancer: An experience from routine tertiary care setting. *Indian Journal of Cancer*. Jan-Mar 2017;54(1):276-279. doi:<https://dx.doi.org/10.4103/0019-509X.219606>
14. von Verschuer U, Schnell R, Tessen HW, et al. Treatment, outcome and quality of life of 1239 patients with advanced non-small cell lung cancer - final results from the prospective German TLK cohort study. *Research Support, Non-U.S. Gov't. Lung Cancer*. 10 2017;112:216-224. doi:<https://dx.doi.org/10.1016/j.lungcan.2017.07.031>
15. Xu J, Liu X, Yang S, Zhang X, Shi Y. Efficacy of icotinib in lung squamous-cell cancer: A real-world experience from single institution. *Asia-Pacific Journal of Clinical Oncology*. Dec 2017;13(6):379-384. doi:<https://dx.doi.org/10.1111/ajco.12669>
16. Aggarwal H, Bayo K, Han Y, Muehlenbein CE, Zhu YE, Kim JS. Real-world maintenance therapy and survival outcomes for pembrolizumab plus pemetrexed and platinum for non-small-cell lung cancer in USA. *Immunotherapy*. 01 Mar 2023;15(4):267-281. doi:<https://dx.doi.org/10.2217/imt-2022-0166>
17. Akazawa Y, Yoshikawa A, Kanazu M, Yano Y, Yamaguchi T, Mori M. Non-small cell lung cancer with tumor proportion score > 90% could increase the risk of severe immune-related adverse events in first-line treatments with immune checkpoint inhibitors: A retrospective single-center study. *Thoracic Cancer*. September 2022;13(17):2450-2458. doi:<https://dx.doi.org/10.1111/1759-7714.14576>
18. Attili I, Valenza C, Santoro C, et al. Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 < 50%. *Frontiers in Oncology*. 10 Aug 2022;12 (no pagination)980765. doi:<https://dx.doi.org/10.3389/fonc.2022.980765>
19. Banna GL, Signorelli D, Metro G, et al. Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab. *Translational Lung Cancer Research*. August 2020;9(4):1533-1542. doi:<https://dx.doi.org/10.21037/tlcr-19-583>
20. Bjornhart B, Hansen KH, Jorgensen TL, Herrstedt J, Schytte T. Efficacy and safety of immune checkpoint inhibitors in a Danish real life non-small cell lung cancer population: a retrospective cohort study. *Acta Oncologica*. 03 Jul 2019;58(7):953-961. doi:<https://dx.doi.org/10.1080/0284186X.2019.1615636>
21. Bureau M, Chatellier T, Perennec T, et al. Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 $\geq$ 50% non-small cell lung cancer patients treated with first-line pembrolizumab. *Cancer Immunology, Immunotherapy*. July 2022;71(7):1747-1756. doi:<https://dx.doi.org/10.1007/s00262-021-03108-x>
22. Cavaille F, Peretti M, Garcia ME, et al. Real-world efficacy and safety of pembrolizumab in patients with non-small cell lung cancer: a retrospective observational study. *Tumori*. 27 May 2020;300891620926244. doi:<https://dx.doi.org/10.1177/0300891620926244>
23. Chang KC, Shao SC, Chen HY, Chan YY, Fang YF. Comparative Effectiveness and Safety of Standard-Dose and Low-Dose Pembrolizumab in Patients with Non-Small-Cell Lung Cancer: A Multi-Institutional Cohort Study in Taiwan. *Cancers*. March-1 2022;14(5) (no pagination)1157. doi:<https://dx.doi.org/10.3390/cancers14051157>
24. Chen Y, Wang Y, Yang Z, et al. Pembrolizumab Alone or Combined With Chemotherapy in Advanced NSCLC With PD-L1 $\geq$ 50%: Results of a Retrospective Study. *Frontiers in Oncology*. 28 Jun 2021;11 (no pagination)691519. doi:<https://dx.doi.org/10.3389/fonc.2021.691519>

25. Cortellini A, Tiseo M, Banna GL, et al. Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50 . Multicenter Study. *Cancer Immunology, Immunotherapy*. Nov 2020;69(11):2209-2221. doi:<https://dx.doi.org/10.1007/s00262-020-02613-9>
26. Descourt R, Greillier L, Perol M, et al. First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score $\geq 50\%$) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESKEYP GFPC study). *Cancer Immunology, Immunotherapy*. January 2023;72(1):91-99. doi:<https://dx.doi.org/10.1007/s00262-022-03232-2>
27. Di Noia V, D'Argento E, Pilotto S, et al. Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory "FoRECATT" study. *Cancer Immunology, Immunotherapy*. June 2021;70(6):1583-1592. doi:<https://dx.doi.org/10.1007/s00262-020-02788-1>
28. Dube-Pelletier M, Labbe C, Cote J, Pelletier-St-Pierre AA. Pembrolizumab Every 6 Weeks Versus Every 3 Weeks in Advanced Non-Small Cell Lung Cancer. *The oncologist*. 2023;26doi:<https://dx.doi.org/10.1093/oncolo/oyad182>
29. Dudnik E, Moskovitz M, Daher S, et al. Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data. *Lung Cancer*. December 2018;126:217-223. doi:<https://dx.doi.org/10.1016/j.lungcan.2017.11.015>
30. Dudnik E, Kareff S, Moskovitz M, et al. Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung. *Journal for ImmunoTherapy of Cancer*. 17 Feb 2021;9(2) (no pagination)e001999. doi:<https://dx.doi.org/10.1136/jitc-2020-001999>
31. Eklund EA, Wiel C, Fagman H, et al. KRAS mutations impact clinical outcome in metastatic non-small cell lung cancer. Preprint. medRxiv. 2021;28doi:<https://dx.doi.org/10.1101/2021.11.27.21266822>
32. Faoro L, Brusegan A, Russi A, et al. Analysis of the relation between adverse events and overall survival in patients treated with pembrolizumab as a first-line treatment for metastatic NSCLC. *BMC Pharmacology and Toxicology*. December 2023;24(1) (no pagination)32. doi:<https://dx.doi.org/10.1186/s40360-023-00663-0>
33. Frost N, Kollmeier J, Misch D, et al. Pembrolizumab as First-Line Palliative Therapy in PD-L1 Overexpressing ($\geq 50\%$) NSCLC: Real-world Results with Special Focus on PS ≥ 2 , Brain Metastases, and Steroids. *Clinical Lung Cancer*. September 2021;22(5):411-422. doi:<https://dx.doi.org/10.1016/j.clc.2021.02.001>
34. Frost N, Kollmeier J, Vollbrecht C, et al. KRASG12C/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high ($\geq 50\%$) lung adenocarcinoma. *Translational Lung Cancer Research*. 2021;10(2):737.
35. Fujimoto D, Miura S, Yoshimura K, et al. Pembrolizumab plus chemotherapy-induced pneumonitis in chemo-naïve patients with non-squamous non-small cell lung cancer: A multicentre, retrospective cohort study. *European Journal of Cancer*. June 2021;150:63-72. doi:<https://dx.doi.org/10.1016/j.ejca.2021.03.016>
36. Geiger-Gritsch S, Olschewski H, Kocher F, et al. Real-world experience with anti-PD-1/PD-L1 monotherapy in patients with non-small cell lung cancer: A retrospective Austrian multicenter study. *Wiener Klinische Wochenschrift*. November 2021;133(21-22):1122-1130. doi:<https://dx.doi.org/10.1007/s00508-021-01940-w>
37. Genova C, Tasso R, Rosa A, et al. Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell Lung Cancer Patients Treated with Immune

Checkpoint Inhibitors. *Cells*. March 2023;12(6) (no pagination)832.
doi:<https://dx.doi.org/10.3390/cells12060832>

38. Goto Y, Tamura A, Matsumoto H, et al. First-Line Pembrolizumab Monotherapy for Advanced NSCLC With Programmed Death-Ligand 1 Expression Greater Than or Equal to 50%: Real-World Study Including Older Patients in Japan. *JTO Clin Res Rep*. Sep 2022;3(9):100397.
doi:<https://dx.doi.org/10.1016/j.jtocrr.2022.100397>

39. Hasegawa T, Yanagitani N, Ninomiya H, et al. Association between the efficacy of pembrolizumab and low STK11/LKB1 expression in high-PD-L1-expressing non-small-cell lung cancer. *in vivo*. 2020;34(5):2997-3003.

40. Holtzman L, Moskovitz M, Urban D, et al. dNLR-Based Score Predicting Overall Survival Benefit for The Addition of Platinum-Based Chemotherapy to Pembrolizumab in Advanced NSCLC With PD-L1 Tumor Proportion Score $\geq$ 50%. *Clinical Lung Cancer*. 2022;23(2):122-134.

41. Hu F, Peng J, Niu Y, Mao X, Zhao Y, Jiang L. Clinical predictors of treatment efficacy and a prognostic nomogram in patients with lung adenocarcinoma receiving immune checkpoint inhibitors: a retrospective study. *J. Oct* 2022;14(10):4096-4112. doi:<https://dx.doi.org/10.21037/jtd-22-1270>

42. Ikeuchi N, Igata F, Kinoshita E, et al. Real-world Efficacy and Safety of Atezolizumab Plus Bevacizumab, Paclitaxel and Carboplatin for First-line Treatment of Japanese Patients With Metastatic Non-squamous Non-small Cell Lung Cancer. *Anticancer Research*. February 2023;43(2):713-724.
doi:<https://dx.doi.org/10.21873/anticancer.16210>

43. Imai H, Kishikawa T, Minemura H, et al. Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancer. Multicenter Study. *Cancer Medicine*. 10 2021;10(20):6971-6984.
doi:<https://dx.doi.org/10.1002/cam4.4220>

44. Isono T, Kagiya N, Shibata S, et al. A retrospective analysis of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for advanced or recurrent non-small cell lung cancer. *Thoracic Cancer*. May 2021;12(9):1387-1397. doi:<https://dx.doi.org/10.1111/1759-7714.13915>

45. Ivanovic M, Knez L, Herzog A, Kovacevic M, Cufer T. Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Real-World Data from an Academic Central and Eastern European Center. *Oncologist*. December 2021;26(12):e2143-e2150. doi:<https://dx.doi.org/10.1002/onco.13909>

46. Kaira K, Yamaguchi O, Kawasaki T, et al. Prognostic significance of tumor infiltrating lymphocytes on first-line pembrolizumab efficacy in advanced non-small cell lung cancer. *Discover Oncology*. December 2023;14(1) (no pagination)6. doi:<https://dx.doi.org/10.1007/s12672-023-00615-4>

47. Lang D, Huemer F, Rinnerthaler G, et al. Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study. *Targeted oncology*. 2019;25doi:<https://dx.doi.org/10.1007/s11523-019-00679-9>

48. Lenci E, Cantini L, Pecci F, et al. The gustave roussy immune (Grim)-score variation is an early-on-treatment biomarker of outcome in advanced non-small cell lung cancer (nscl) patients treated with first-line pembrolizumab. *Journal of Clinical Medicine*. 01 Mar 2021;10(5):1-14.
doi:<https://dx.doi.org/10.3390/jcm10051005>

49. Lester J, Escriu C, Khan S, et al. Retrospective analysis of real-world treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer starting first-line systemic therapy in the United Kingdom. *BMC Cancer*. December 2021;21(1) (no pagination)515.
doi:<https://dx.doi.org/10.1186/s12885-021-08096-w>

50. Li Q, Zhou Q, Zhao S, et al. KRAS mutation predict response and outcome in advanced non-small cell lung carcinoma without driver alterations receiving PD-1 blockade immunotherapy combined with platinum-based chemotherapy: a retrospective cohort study from China. *Translational Lung Cancer Research*. October 2022;11(10):2136-2147. doi:<https://dx.doi.org/10.21037/tlcr-22-655>
51. Liao J, Liu C, Long Q, et al. Direct Comparison Between the Addition of Pembrolizumab or Bevacizumab for Chemotherapy-Based First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer Lacking Driver Mutations. *Frontiers in Oncology*. 29 Sep 2021;11 (no pagination)752545. doi:<https://dx.doi.org/10.3389/fonc.2021.752545>
52. Liu SV, Hu X, Li Y, Zhao B, Burke T, Velcheti V. Pembrolizumab-combination therapy for previously untreated metastatic nonsquamous NSCLC: Real-world outcomes at US oncology practices. *Frontiers in Oncology*. 17 Oct 2022;12 (no pagination)999343. doi:<https://dx.doi.org/10.3389/fonc.2022.999343>
53. Liu SV, Rai P, Wang D, Hu X, Schwarzenberger PO. First-Line Pembrolizumab Plus Chemotherapy for Advanced Squamous NSCLC: Real-World Outcomes at U.S. Oncology Practices. *JTO Clin Res Rep*. Feb 2023;4(2):100444. doi:<https://dx.doi.org/10.1016/j.jtocrr.2022.100444>
54. Low JL, Huang Y, Sooi K, et al. Low dose pembrolizumab in the treatment of advanced non-small cell lung cancer. *International journal of cancer*. 2021;26doi:<https://dx.doi.org/10.1002/ijc.33534>
55. Matsumoto H, Kobayashi N, Somekawa K, et al. Pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in patients with non-small-cell lung cancer: A multicenter retrospective trial. *Thoracic Cancer*. January 2022;13(2):228-235. doi:<https://dx.doi.org/10.1111/1759-7714.14252>
56. Nindra U, Shahnam A, Stevens S, et al. Influence of EGFR mutation status and PD-L1 expression in stage III unresectable non-small cell lung cancer treated with chemoradiation and consolidation durvalumab. *Asia Pacific Journal of Clinical Oncology*. 2023;doi:<https://dx.doi.org/10.1111/ajco.13940>
57. Nokihara H, Kijima T, Yokoyama T, et al. Real-World Treatments and Clinical Outcomes in Advanced NSCLC without Actionable Mutations after Introduction of Immunotherapy in Japan. *Cancers*. June-2 2022;14(12) (no pagination)2846. doi:<https://dx.doi.org/10.3390/cancers14122846>
58. Noordhof AL, Damhuis RAM, Hendriks LEL, et al. Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy. *Lung Cancer*. May 2021;155:163-169. doi:<https://dx.doi.org/10.1016/j.lungcan.2021.04.001>
59. Amrane K, Geier M, Corre R, et al. First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 $\geq 50\%$ in a multicenter real-life cohort: The PEMBREIZH study. *Cancer medicine*. 2020;05doi:<https://dx.doi.org/10.1002/cam4.2806>
60. Perol M, Felip E, Dafni U, et al. Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data. *Annals of Oncology*. May 2022;33(5):511-521. doi:<https://dx.doi.org/10.1016/j.annonc.2022.02.008>
61. Raez LE, Arrieta O, Chamorro DF, et al. Durvalumab After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: Inferior Outcomes and Lack of Health Equity in Hispanic Patients Treated With PACIFIC Protocol (LA1-CLICaP). *Frontiers in Oncology*. 12 Jul 2022;12 (no pagination)904800. doi:<https://dx.doi.org/10.3389/fonc.2022.904800>
62. Renaud E, Ricordel C, Corre R, et al. Pembrolizumab plus pemetrexed-carboplatin combination in first-line treatment of advanced non-squamous non-small cell lung cancer: a multicenter real-life study

(CAP29). *Translational Lung Cancer Research*. 28 Feb 2023;12(2):266-276.
doi:<https://dx.doi.org/10.21037/tlcr-22-556>

63. Sanchez-Gastaldo A, Munoz-Fuentes MA, Molina-Pinelo S, Alonso-Garcia M, Boyero L, Bernabe-Caro R. Correlation of peripheral blood biomarkers with clinical outcomes in NSCLC patients with high PD-L1 expression treated with pembrolizumab. *Translational Lung Cancer Research*. June 2021;10(6):2509-2522. doi:<https://dx.doi.org/10.21037/tlcr-21-156>
64. Seban RD, Assie JB, Giroux-Leprieur E, et al. FDG-PET biomarkers associated with long-term benefit from first-line immunotherapy in patients with advanced non-small cell lung cancer. *Annals of Nuclear Medicine*. December 2020;34(12):968-974. doi:<https://dx.doi.org/10.1007/s12149-020-01539-7>
65. Seban RD, Assie JB, Giroux-Leprieur E, et al. Prognostic value of inflammatory response biomarkers using peripheral blood and [18F]-FDG PET/CT in advanced NSCLC patients treated with first-line chemo- or immunotherapy. *Lung Cancer*. September 2021;159:45-55.
doi:<https://dx.doi.org/10.1016/j.lungcan.2021.06.024>
66. Shah M, Hubbard RA, Mamtani R, Marmarelis ME, Hennessy S. Very high PD-L1 expression as a prognostic indicator of overall survival among patients with advanced non-small cell lung cancer receiving anti-PD-(L)1 monotherapies in routine practice. *Pharmacoepidemiology and Drug Safety*. October 2022;31(10):1121-1126. doi:<https://dx.doi.org/10.1002/pds.5487>
67. Shah M, Marmarelis ME, Mamtani R, Hennessy S. Association Between Survival and Very High Versus High PD-L1 Expression in Patients Receiving Pembrolizumab as First-line Treatment for Advanced Non-Small Cell Lung Cancer. *Clinical Lung Cancer*. December 2022;23(8):731-736.
doi:<https://dx.doi.org/10.1016/j.clcc.2022.07.003>
68. Shah M, Mamtani R, Marmarelis ME, Hennessy S. Chemoimmunotherapy vs. Immunotherapy for First Line Treatment of Advanced Non-small Cell Lung Cancer With a PD-L1 Expression $\geq 50\%$ or $\geq 90\%$. *Clinical Lung Cancer*. May 2023;24(3):235-243. doi:<https://dx.doi.org/10.1016/j.clcc.2023.02.007>
69. Shalata W, Zolnoorian J, Migliozi G, et al. Long-Lasting Therapeutic Response following Treatment with Pembrolizumab in Patients with Non-Small Cell Lung Cancer: A Real-World Experience. *International Journal of Molecular Sciences*. Mar 21 2023;24(6):21.
doi:<https://dx.doi.org/10.3390/ijms24065938>
70. Anpalakhan S, Huddar P, Behrouzi R, et al. The Effects of GCSF Primary Prophylaxis on Survival Outcomes and Toxicity in Patients with Advanced Non-Small Cell Lung Cancer on First-Line Chemoimmunotherapy: A Sub-Analysis of the Spinnaker Study. *International Journal of Molecular Sciences*. January 2023;24(2) (no pagination)1746. doi:<https://dx.doi.org/10.3390/ijms24021746>
71. Anpalakhan S, Huddar P, Behrouzi R, et al. Immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy: a Spinnaker study sub-analysis. *Frontiers in Oncology*. 2023;13 (no pagination)1163768.
doi:<https://dx.doi.org/10.3389/fonc.2023.1163768>
72. Banna GL, Cantale O, Muthuramalingam S, et al. Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study. *International Immunopharmacology*. September 2022;110 (no pagination)108985. doi:<https://dx.doi.org/10.1016/j.intimp.2022.108985>
73. Tamayo-Bermejo R, del Rio-Valencia JC, Mora-Rodriguez B, Munoz-Castillo I. Effectiveness and safety of pembrolizumab monotherapy in patients with locally advanced or metastatic non-small-cell lung cancer. *Journal of Oncology Pharmacy Practice*. January 2023;29(1):138-144.
doi:<https://dx.doi.org/10.1177/1078155221106117>

74. Tamiya M, Tamiya A, Hosoya K, et al. Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001). *Investigational New Drugs*. 01 Dec 2019;37(6):1266-1273. doi:<https://dx.doi.org/10.1007/s10637-019-00843-y>
75. Tang M, Lee CK, Lewis CR, et al. Generalizability of immune checkpoint inhibitor trials to real-world patients with advanced non-small cell lung cancer. *Lung Cancer*. April 2022;166:40-48. doi:<https://dx.doi.org/10.1016/j.lungcan.2022.01.024>
76. Tibaldi C, Mazzone F, Scotti V, et al. Pembrolizumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: Analysis of Prognostic Factors of Outcomes. *Anti-Cancer Agents in Medicinal Chemistry*. April 2022;22(7):1278-1285. doi:<https://dx.doi.org/10.2174/1871520621666210727112212>
77. Tsai JS, Wei SH, Chen CW, et al. Pembrolizumab and Chemotherapy Combination Prolonged Progression-Free Survival in Patients with NSCLC with High PD-L1 Expression and Low Neutrophil-to-Lymphocyte Ratio. *Pharmaceuticals*. November 2022;15(11) (no pagination)1407. doi:<https://dx.doi.org/10.3390/ph15111407>
78. Veccia A, Sforza V, Vattermi E, et al. Pretreatment lung immune prognostic index as biomarker in advanced non-small-cell lung cancer patients receiving first line pembrolizumab. *Immunotherapy*. 2021;30doi:<https://dx.doi.org/10.2217/imt-2021-0002>
79. Velcheti V, Chandwani S, Chen X, Pietanza MC, Piperdi B, Burke T. Outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS $\geq$ 50%) metastatic NSCLC at US oncology practices. *Immunotherapy*. 2019;11(18):1541-1554. doi:<https://dx.doi.org/10.2217/imt-2019-0177>
80. Velcheti V, Hu X, Piperdi B, Burke T. Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices. *Scientific reports*. 28 Apr 2021;11(1):9222. doi:<https://dx.doi.org/10.1038/s41598-021-88453-8>
81. Velcheti V, Hu X, Yang L, Pietanza MC, Burke T. Long-Term Real-World Outcomes of First-Line Pembrolizumab Monotherapy for Metastatic Non-Small Cell Lung Cancer With $\geq$ 50% Expression of Programmed Cell Death-Ligand 1. *Frontiers in Oncology*. 25 Mar 2022;12 (no pagination)834761. doi:<https://dx.doi.org/10.3389/fonc.2022.834761>
82. Wang X, Niu X, An N, Sun Y, Chen Z. Comparative Efficacy and Safety of Immunotherapy Alone and in Combination With Chemotherapy for Advanced Non-small Cell Lung Cancer. *Frontiers in Oncology*. 18 Mar 2021;11 (no pagination)611012. doi:<https://dx.doi.org/10.3389/fonc.2021.611012>
83. Waterhouse D, Lam J, Betts KA, et al. Real-world outcomes of immunotherapy-based regimens in first-line advanced non-small cell lung cancer. *Lung Cancer*. June 2021;156:41-49. doi:<https://dx.doi.org/10.1016/j.lungcan.2021.04.007>
84. Xu B, Cheng H, Li K, et al. Carboplatin and nab-paclitaxel chemotherapy with or without atezolizumab as front-line management for treatment-naïve metastatic nonsquamous non-small cell lung cancer with PD-L1 staining: a retrospective study. *Journal of Cancer Research and Clinical Oncology*. November 2022;148(11):3029-3038. doi:<https://dx.doi.org/10.1007/s00432-021-03873-3>
85. Yoneda T, Sone T, Koba H, et al. Long-Term Survival of Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor Monotherapy in Real-World Settings. *Clinical Lung Cancer*. September 2022;23(6):467-476. doi:<https://dx.doi.org/10.1016/j.clcc.2022.03.008>
86. Yuasa I, Hamaji M, Ozasa H, et al. Outcomes of immune checkpoint inhibitors for postoperative recurrence of non-small cell lung cancer. *General Thoracic and Cardiovascular Surgery*. 2023;doi:<https://dx.doi.org/10.1007/s11748-023-01920-z>

87. Zayas-Soriano M, Bonete-Sanchez M, Campillo-Lopez J, Marcos-Ribes B, Hernandez-Guio A, Aznar-Saliente MT. Clinical efficacy and safety of anti PD-1/PD-L1 antibodies as monotherapy in patients with non-small-cell lung cancer. *Observational Study. Farm. Dec 03 2020;45(1):22-27. Efectividad y seguridad en la practica clinica de anticuerpos anti PD-1/PD-L1 en monoterapia en el cancer de pulmon no microcitico.* doi:<https://dx.doi.org/10.7399/fh.11478>
88. Zhang J, Wu D, Zhang Z, et al. Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study. *Technology in Cancer Research and Treatment.* 2021;20(no pagination)doi:<https://dx.doi.org/10.1177/15330338211039676>

Advanced renal cell carcinoma

1. Boegemann M, Hubbe M, Thomaidou D, et al. Sunitinib treatment modification in first-line metastatic renal cell carcinoma: Analysis of the STAR-TOR Registry. *Anticancer Research*. November 2018;38(11):6413-6422. doi:<https://dx.doi.org/10.21873/anticancer.13002>
2. Buti S, Bersanelli M, Maines F, et al. First-Line PAZopanib in NOn-clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study. *Clinical Genitourinary Cancer*. August 2017;15(4):e609-e614. doi:<https://dx.doi.org/10.1016/j.clgc.2016.12.024>
3. Cecere SC, Rossetti S, Cavaliere C, et al. Pazopanib in Metastatic Renal Cancer: A "Real-World" Experience at National Cancer Institute "Fondazione G. Pascale". *Front Pharmacol*. 2016;7:287. doi:<https://dx.doi.org/10.3389/fphar.2016.00287>
4. Chrom P, Stec R, Semeniuk-Wojtas A, Bodnar L, Spencer NJ, Szczylik C. Fuhrman Grade and Neutrophil-To-Lymphocyte Ratio Influence on Survival in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors. *Clinical Genitourinary Cancer*. 01 Oct 2016;14(5):457-464. doi:<https://dx.doi.org/10.1016/j.clgc.2016.02.005>
5. Coelho RC, Reinert T, Campos F, et al. Sunitinib treatment in patients with advanced renal cell cancer: the Brazilian National Cancer Institute (INCA) experience. *International braz j urol : official journal of the Brazilian Society of Urology*. 01 Jul 2016;42(4):694-703. doi:<https://dx.doi.org/10.1590/S1677-5538.IBJU.2015.0226>
6. Ezz El Din M. Utilization of sunitinib for renal cell cancer: an Egyptian university hospital experience. *Asian Pac J Cancer Prev*. 2016;17:3161-3166.
7. Edesa WA, Abdelmalek RR. Efficacy and toxicity of sunitinib in metastatic renal cell carcinoma patients in Egypt. *Asian Pacific Journal of Cancer Prevention*. 2015;16(5):1971-1976.
8. El Din ME. Sunitinib 4/2 Versus 2/1 schedule for patients with metastatic renal cell carcinoma: tertiary care hospital experience. *Clinical Genitourinary Cancer*. 2017;15(3):e455-e462.
9. Joshi R, Rawal S. Targeted Therapy for Renal Cell Carcinoma: a Prospective study. *Journal of the Nepal Medical Association*. 2015;53(198)
10. Joshi A, Ramaswamy A, Noronha V, et al. Efficacy and safety of sorafenib in advanced renal cell cancer and validation of Heng criteria. *Indian Journal of Cancer*. 2016;53(3):423-428.
11. Kim MJ, Park SH, Lee J-L, Lee S-H, Lee SJ, Lim HY. A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma. *BMC urology*. 2016;16(1):1-7.
12. Kim MS, Chung HS, Hwang EC, et al. Efficacy of first-line targeted therapy in real-world Korean patients with metastatic renal cell carcinoma: focus on sunitinib and pazopanib. *Journal of Korean medical science*. 2018;33(51)
13. Köstek O, Yılmaz E, Hacıoğlu MB, et al. Changes in skeletal muscle area and lean body mass during pazopanib vs sunitinib therapy for metastatic renal cancer. *Cancer chemotherapy and pharmacology*. 2019;83:735-742.
14. Kucharz J, Dumnicka P, Giza A, et al. Radiological response and neutrophil-to-lymphocyte ratio as predictive factors for progression-free and overall survival in metastatic renal cell carcinoma patients treated with sunitinib. *Medical Science and Research*. 2019:31-45.
15. Liu C, Cao F, Xing W, et al. Efficacy of cryoablation combined with sorafenib for the treatment of advanced renal cell carcinoma. *International Journal of Hyperthermia*. 2019;36(1):219-227.

16. Maráz A, Cserhádi A, Uhercsák G, et al. Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinoma. *BMC Cancer*. 2018;18:1-12.
17. Mir MH, Chungal KH, Aziz SA, Bhat GM, Lone AR. Sunitinib in metastatic renal cell carcinoma (mRCC): a developing country experience. Do our patients behave differently than the Western patients? *International urology and nephrology*. 2016;48:1811-1816.
18. Miyake H, Miyazaki A, Imai S, Harada K-i, Fujisawa M. Early tumor shrinkage under treatment with first-line tyrosine kinase inhibitors as a predictor of overall survival in patients with metastatic renal cell carcinoma: a retrospective multi-institutional study in Japan. *Targeted oncology*. 2016;11:175-182.
19. Munárriz J, Reynés G, Sánchez-Lorenzo L, et al. Sunitinib rechallenge in advanced renal cell carcinoma: outcomes of a multicenter retrospective study. *Cancer Chemotherapy and Pharmacology*. 2019;84:781-789.
20. Patel K, Panchal H, Karanwal A, Parekh B, Shah S, Prasad S. Sunitinib in metastatic renal cell carcinoma: Experience from single center study, efficacy and safety. *Indian Journal of Cancer*. 2016;53(1):118-122.
21. Pérez-Valderrama B, Arija JA, Sánchez AR, et al. Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish Oncologic Genitourinary Group (SOGUG) SPAZO study. *Annals of Oncology*. 2016;27(4):706-711.
22. Procopio G, Bamias A, Schmidinger M, et al. Real-world Effectiveness and Safety of Pazopanib in Patients With Intermediate Prognostic Risk Advanced Renal Cell Carcinoma. *Clinical Genitourinary Cancer*. 2019/06/01/ 2019;17(3):e526-e533. doi:<https://doi.org/10.1016/j.clgc.2019.01.018>
23. Poprach A, Fiala O, Chloupková R, et al. Pazopanib for metastatic renal cell carcinoma: a registry-based analysis of 426 patients. *Anticancer Research*. 2018;38(1):449-456.
24. Qiu J, Liu D, Yan Z, et al. Therapeutic effect and adverse reaction of sorafenib in the treatment of advanced renal cancer. *Oncology Letters*. 2019;17(2):1547-1550.
25. Queiroz Muniz D, Ratto B, Yang H, et al. Real-world effectiveness and tolerability of pazopanib as first targeted therapy in metastatic renal cell carcinoma: a retrospective chart review in Latin America. *Advances in Therapy*. 2019;36:3446-3457.
26. Sabanathan D, Zhang A, Fox P, et al. Dose individualization of sunitinib in metastatic renal cell cancer: toxicity-adjusted dose or therapeutic drug monitoring. *Cancer Chemotherapy and Pharmacology*. 2017;80:385-393.
27. Saxena M, Madabhavi I, Patel A, Panchal H, Anand A. Experience of Sorafenib as First-Line Treatment in Metastatic Renal Cell Carcinoma in a Tertiary Care Centre. *International Journal of Hematology-Oncology and Stem Cell Research*. 2018;12(3):197.
28. Yamamoto K, Hara T, Nakagawa T, et al. Association of expression levels or activation status of STAT3 with treatment outcomes of sunitinib in patients with renal cell carcinoma. *Targeted Oncology*. 2018;13:371-378.
29. Harada KI, Sato R, Bando Y, et al. Efficacy and safety of pembrolizumab and axitinib as first-line treatment for patients with advanced renal cell carcinoma: Real-world experience in Japan. *International Journal of Urology*. 2023;doi:<https://dx.doi.org/10.1111/iju.15230>
30. Iinuma K, Kameyama K, Kawada K, et al. Efficacy and safety of nivolumab and ipilimumab for advanced or metastatic renal cell carcinoma: A multicenter retrospective cohort study. *Current Oncology*. 2021;28(2):1402-1411. doi:<https://dx.doi.org/10.3390/currenol28020133>

31. Iinuma K, Yamada T, Kameyama K, et al. The Efficacy and Safety of Immune Checkpoint Inhibitor and Tyrosine Kinase Inhibitor Combination Therapy for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Real-World Cohort Study. *Cancers*. February 2023;15(3) (no pagination)947. doi:<https://dx.doi.org/10.3390/cancers15030947>
32. Izumi K, Inoue M, Washino S, et al. Clinical outcomes of nivolumab plus ipilimumab in patients with metastatic non-clear cell renal cell carcinoma: Real-world data from a Japanese multicenter retrospective study. *International Journal of Urology*. 2022;doi:<https://dx.doi.org/10.1111/iju.15128>
33. Jo H, Hong J, Kim H, et al. A Retrospective Study of First-Line Therapy Involving Immune Checkpoint Inhibitors in Patients With Poor Risk Metastatic Renal Cell Carcinoma. *Frontiers in Oncology*. 28 Apr 2022;12 (no pagination)874385. doi:<https://dx.doi.org/10.3389/fonc.2022.874385>
34. Kato R, Kojima T, Sazuka T, et al. A multicentre retrospective study of nivolumab plus ipilimumab for untreated metastatic renal cell carcinoma. *Anticancer Research*. December 2021;41(12):6199-6209. doi:<https://dx.doi.org/10.21873/anticancer.15439>
35. Kato T, Fujita K, Minami T, et al. Real-world efficacy and safety of nivolumab plus ipilimumab in untreated metastatic renal cell carcinoma, and the impact of previous nephrectomy on clinical outcome: Japanese multi-institutional retrospective study. Multicenter Study. *Int J Clin Oncol*. Oct 2022;27(10):1596-1604. doi:<https://dx.doi.org/10.1007/s10147-022-02215-8>
36. Kim Y, Yang H, Lee WS, et al. High levels of baseline serum IL-10 are associated with reduced clinical benefit from first-line immune checkpoint inhibitor therapy in advanced renal cell carcinoma. *Journal of Cancer*. 2023;14(6):935-942. doi:<https://dx.doi.org/10.7150/jca.81384>
37. Kojima T, Kato R, Sazuka T, et al. Real-world effectiveness of nivolumab plus ipilimumab and second-line therapy in Japanese untreated patients with metastatic renal cell carcinoma: 2-year analysis from a multicenter retrospective clinical study (J-cardinal study). *Japanese journal of clinical oncology*. 03 Nov 2022;52(11):1345-1352. doi:<https://dx.doi.org/10.1093/jjco/hyac124>
38. Rebuzzi SE, Signori A, Buti S, et al. Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program. *ESMO Open*. December 2022;7(6) (no pagination)100634. doi:<https://dx.doi.org/10.1016/j.esmoop.2022.100634>
39. Sang YB, Yang H, Lee WS, et al. High Serum Levels of IL-6 Predict Poor Responses in Patients Treated with Pembrolizumab plus Axitinib for Advanced Renal Cell Carcinoma. *Cancers*. December 2022;14(23) (no pagination)5985. doi:<https://dx.doi.org/10.3390/cancers14235985>
40. Shah NJ, Sura SD, Shinde R, et al. Real-world Treatment Patterns and Clinical Outcomes for Metastatic Renal Cell Carcinoma in the Current Treatment Era. *Eur Urol Open Sci*. Mar 2023;49:110-118. doi:<https://dx.doi.org/10.1016/j.euros.2022.12.015>
41. Tomiyama N, Tasaki Y, Hamamoto S, et al. Hemoglobin and neutrophil levels stratified according to International Metastatic Renal Cell Carcinoma Database Consortium risk predict the effectiveness of ipilimumab plus nivolumab in patients with advanced metastatic renal cell carcinoma. *International Journal of Urology*. 2023;doi:<https://dx.doi.org/10.1111/iju.15198>
42. Ueda K, Ogasawara N, Ito N, et al. Prognostic Value of Absolute Lymphocyte Count in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab plus Ipilimumab. *Journal of Clinical Medicine*. March 2023;12(6) (no pagination)2417. doi:<https://dx.doi.org/10.3390/jcm12062417>
43. Zakharia Y, Thomaidou D, Li B, et al. Real-World Therapy Management and Outcomes of First-Line Axitinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma in the United States.

Frontiers in Oncology. 19 May 2022;12 (no pagination)861189.
doi:<https://dx.doi.org/10.3389/fonc.2022.861189>

44. Zarrabi KK, Handorf E, Miron B, et al. Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma. *The oncologist*. 08 Feb 2023;28(2):157-164. doi:<https://dx.doi.org/10.1093/oncolo/oyac195>